Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

468.13 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
54 55 Next >
3 Biotech Stocks That Could Be Multibaggers in the Making
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies. 
Via InvestorPlace
Biotech And Healthcare Portfolio Playbook For December 2023/24
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. 
Via Talk Markets
5 Stocks You Can Confidently Invest $500 In Right Now
These companies could significantly grow your investment over the long haul. 
Via The Motley Fool
2 Healthcare Stocks That Could Help Set You Up for Life
Both companies are leaders in their fields. 
Via The Motley Fool
Is Vertex Pharmaceuticals Stock a Buy Now?
The company is close to another breakthrough. 
Via The Motley Fool
How Is The Market Feeling About Vertex Pharmaceuticals?
Via Benzinga
Investing in These 3 Stocks Now Could Make You a Millionaire Retiree
These innovators should have tremendous long-term growth prospects. 
Via The Motley Fool
4 First-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The innovation-fueled Nasdaq Composite is still 11% below its all-time high, which means bargains abound for opportunistic investors. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Prediction: 3 Stocks That Could Trounce the Market
These stocks have what it takes to be huge winners over the next several years. 
Via The Motley Fool
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today
Via Benzinga
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio? 
Via The Motley Fool
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
The stock is trading below its peak, reached a couple of years ago. 
Via The Motley Fool
Barron's Weekend Stock Picks: Disney, Palantir And Cisco's Calamitous Outlook
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. 
Via Benzinga
Why CRISPR Therapeutics Stock Is Jumping Again Today
The stock continues to enjoy momentum from a key regulatory approval. 
Via The Motley Fool
Williams-Sonoma, Uber And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by 0.1% on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
InvestorNewsBreaks – Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Featured in Barron’s Article for Potential Near ‘Breakthrough’
Via Investor Brand Network
Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug
The drug will sell under the brand name Casgevy in the UK for two blood diseases. 
Via Investor's Business Daily
What's Going On With Crispr Therapeutics Stock Thursday?
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene- 
Via Benzinga
CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy
CRSP stock is up on U.K. authorization for its gene therapy treatment for sickle cell anemia. CRISPR hopes for FDA authorization next spring. 
Via InvestorPlace
Exposures Product Safety
UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia
The U.K. 
Via Benzinga
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks
You might not get a better chance to invest in these disruptive companies. 
Via The Motley Fool
2 Stocks to Buy Hand Over Fist as the S&P 500 Rockets Higher
These stocks look reasonably priced today considering their long-term prospects. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Most stocks aren't truly revolutionary. These really are. 
Via The Motley Fool
1 No-Brainer Stock to Buy and Hold for 10 Years
This company has been in the news for much of the year. 
Via The Motley Fool
MarketBeat Week in Review – 11/6 - 11/10
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS